Navigation Links
BioSpecifics Announces Positive Results From Clinical Trial in Canine Lipomas
Date:1/6/2011

3/4 of the dose used in previous human clinical trials. Based on this dose escalation study the Company selected the dose for Chien-802.

Chien-802 was designed to evaluate the efficacy of injectable collagenase in canine lipoma in four healthy dogs with subcutaneous lipomas. Inclusion criteria required the lipoma to be benign, superficial and easily measureable. All dogs had a second lipoma that was untreated and used as a control. At 90 days post injection, in the three evaluable dogs, the lipoma size was 0%, 0% or 7% of the original size as measured by a CT scan. By contrast, the untreated lipomas were 129%, 113% and 128% of the original size at day 90. Thus, the treated lipomas showed a 97% reduction in the size of the lipoma and an increase in the size of the untreated controls of 23%.  Based on the positive results from Chien-802, BioSpecifics has begun enrollment in a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy of purified collagenase for injection for the treatment of canine lipomas.

The Company's preliminary results from an ongoing marketing survey indicate that veterinarians perform lipoma excision surgery on an average of 25 dogs per year, costing approximately $635 million annually.  

The American Veterinary Medical Association estimates that 47,000 veterinarians practice on small animals. Based on the data from BioSpecifics' survey of veterinarians, the veterinarians estimate that they would use injectable collagenase on an average of 22 dogs per year. BioSpecifics believes that the total potential market for purified collagenase for the treatment of canine lipomas could be 1 million injections in the Unites States annually.

BioSpecifics' strategic partner, Auxilium Pharmaceuticals, Inc. (Auxilium), has the option to license development and marketing rights to this indication, which would trigger an opt-in payment and potential future milestone payments from Auxilium t
'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioSpecifics Technologies Corp. to Present at UBS Global Life Sciences Conference
2. BioSpecifics Technologies Corp. to Present at Rodman & Renshaw 12th Annual Healthcare Conference
3. Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results
4. BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results
5. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2009 Financial Results on November 5, 2009
6. BioSpecifics Technologies Corp. Stock Trading Halted Today
7. BioSpecifics Technologies Corp. To Present at BioCentury NewsMakers in the Biotech Industry Conference
8. BioSpecifics Technologies Corp. to Present at Rodman & Renshaw 11th Annual Healthcare Conference
9. BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results
10. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2009 Financial Results on August 12, 2009
11. BioSpecifics Technologies Corp. to Present at CapStone Investments Third Annual Small-Cap Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... New York (PRWEB) December 23, 2014 According ... the Long Island Affiliate of ITRA Global, the national office ... but steady recovery. This is evidenced by the third ... strong stock market. Low energy costs have held inflation ... The only negative is the housing market remaining soft. , ...
(Date:12/24/2014)... 2014 China Biologic Products, Inc. (NASDAQ: ... fully integrated plasma-based biopharmaceutical company in ... subsidiary, Shandong Taibang Biological Products Co. Ltd., has ... China Food and Drug Administration (the "CFDA") for ... disclosed in the Company,s public filings, the CFDA ...
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014 /PRNewswire/ ... study of mazindol in children with attention deficit/hyperactivity disorder ... December 2014 . The paper, titled ... attention deficit/hyperactivity disorder" ( Konofal et al, ... eCollection 2014 ) shows that mazindol might be ...
(Date:12/22/2014)... 2014 GenomeDx Biosciences today announced that a ... a genomic test for prostate cancer, was able to ... by radical prostatectomy without adjuvant therapy. Although rapid metastasis ... using tumor genomics to identify these men who have ... important advance. The study has been published online ...
Breaking Biology Technology:ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3
... April 8, 2008 Tapestry,Pharmaceuticals, Inc. (Nasdaq: ... a,letter from the Nasdaq Stock Market ("Nasdaq") formally ... 10-K for the period ended January,2, 2008, as ... trading in Tapestry,s common stock will be suspended. ...
... N.Y., April 8, 2008 ShapeGrabber and ... Nikon will serve as a,sales distribution channel ... Ai810 3D laser scanner inspection systems. This ... Instrument,s,extensive network, while enabling Nikon to provide ...
... Policy, SAN CARLOS, Calif., April 8, ... Services (CMS) have approved at-home sleep testing,for ... mandated that,suspected sleep apnea sufferers undergo facility-based ... pressure (CPAP) treatment for,Medicare patients who are ...
Cached Biology Technology:Tapestry Receives Nasdaq Delisting Notice 2ShapeGrabber and Nikon Instruments Inc. Announce Distribution Agreement 2Medicare Approves in Home Sleep Apnea Testing 2
(Date:12/17/2014)... Dec. 15, 2014 Research and Markets ... of the "Samsung Galaxy S5 - Home ... to their offering. ... different sensing technology than the iPhone 5S, Samsung ... in its product. The Galaxy S5 ...
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Practices (GCP) audit to confirm its adherence to ... This accomplishment enables HITLAB to conduct regulated smart ... highest principles for patient safety and research quality. ... healthcare access, quality, and delivery with innovative technology," ...
(Date:12/17/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) ... Chemical Sensor Market 2015-2019" report to their ... One major trend upcoming in this ... in biomedical applications. Chemical sensors help in recording ... during surgical procedures. The Global Chemical Sensor market ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... The Indian Government today released new tiger population numbers for ... in the country that has half of the world,s remaining ... India at 1,706, up from 1,411 during the last count ... reserve in the count, the Sundarbans, that contained 70 tigers. ...
... 28, 2011)Understanding that angioplastya medical treatment used by interventional ... chest to improve blood flowis safe may encourage additional ... individuals with multiple sclerosis, say researchers at the Society ... Ill. "Angioplastythe nonsurgical procedure of threading a thin ...
... Interventional radiologists have been the leaders in the ... 2000, to treat liver cancer. Now, new results from ... with higher doses of Y-90 than previously tried is ... patient,s quality of lifeand can be done on an ...
Cached Biology News:India releases tiger numbers as experts convene 2Interventional radiologists advance MS research: Vein-opening treatment safe 2Interventional radiologists advance MS research: Vein-opening treatment safe 3Interventional radiologists advance MS research: Vein-opening treatment safe 4Interventional Radiology Y-90 Liver Cancer-busting Treatment: Safe, Fast, Extends Life 2Interventional Radiology Y-90 Liver Cancer-busting Treatment: Safe, Fast, Extends Life 3
... Detergent Removal , , ... no cross-reactivity with other proteins , Simple, ... Economical new surface technology, not based ... interfere with protein analysis. SurfactAway offers a ...
... The new FLA-5000 imaging system ... radioisotopic samples as large as ... as low as 25 microns. ... for protein electrophoresis in the ...
General description: MaxiSorp TM surface is ideal for arraying molecules with mixed hydrophilic/hydrophobic domains such as proteins ID clarifier: Maxisorp(tm) with lid...
... of systems provide fast and reliable ... genomics, proteomics and drug development laboratories. ... base configurations; Mini Workstation Series, Application ... All Staccato Application Series systems use ...
Biology Products: